Clinical Trials Sponsored by Merck Sharp & Dohme GmbH, Austria

Total 3974 results

Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Effect of MK-8669 (Ridaforolimus) on QTc Interval in Participants With Advanced Cancer (MK-8669-037)

Metastatic or Locally Advanced Cancer
Merck Sharp & Dohme LLC

Completed

Comparison of Recovery From Rocuronium 1.2 mg/kg Followed by Sugammadex (Org 25969) 16 mg/kg at 3 Minutes With Recovery From Succinylcholine 1.0 mg/kg (19.4.303)(P05946)(MK-8616-026)

Anesthesia, General
Merck Sharp & Dohme LLC

Completed

Comparison of the Efficacy, Safety, and Pharmacokinetics of Sugammadex (MK-8616; Org 25969) in Elderly Participants With Adult Participants (MK-8616-029)

Anesthesia, General
Merck Sharp & Dohme LLC

Completed

Efficacy, Safety and Pharmacokinetics of Sugammadex (Org 25969; MK-8616) at 3 Different Time Points After 0.6 mg/kg Esmeron® in Male Participants (P05940; MK-8616-020).

Neuromuscular Blockade
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-005)

Pneumococcal Infections
Merck Sharp & Dohme LLC

Completed

A Study of the Effects of Single Dose Corticosteroids on Response to Allergens

Allergic Rhinitis
Merck Sharp & Dohme LLC

Completed

Dose Escalation Study With MK-2206 in Patients With Locally Advanced or Metastatic Solid Tumors (MK-2206-002)

Neoplasms | Cancer | Metastatic Solid Tumors | Locally Advanced Tumors
Merck Sharp & Dohme LLC

Completed

Multiple Ascending Dose Study of MK-5160 in Participants With Type 1 and Type 2 Diabetes Mellitus (MK-5160-002)

Type 2 Diabetes Mellitus | Type 1 Diabetes Mellitus

United States
Merck Sharp & Dohme LLC

Completed

Use of Sugammadex at the End of Case in Routine Anesthesia (MK-8616-023)

Anesthesia, General
Merck Sharp & Dohme LLC

Withdrawn

Efficacy and Safety Study of Pembrolizumab (MK-3475) in Combination With Daratumumab in Participants With Relapsed Refractory Multiple Myeloma (MK-3475-668/KEYNOTE-668)

Multiple Myeloma

United States, Canada, France, Israel, Spain, Sweden
Merck Sharp & Dohme LLC

Completed

A Bridging Trial Comparing Sugammadex (Org 25969) at 1-2 Post-Tetanic Count (PTC) in Japanese Participants. Part A (P05957)

Anesthesia, General
Merck Sharp & Dohme LLC

Terminated

Efficacy and Safety Study of Fosaprepitant (MK-0517) Plus Ondansetron Versus Ondansetron Alone for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-044)

Chemotherapy-induced Nausea and Vomiting
Merck Sharp & Dohme LLC

Terminated

Study of MK-8808 for Participants With Follicular Lymphoma (MK-8808-001)

Follicular Lymphoma
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety and Immunogenicity of Inactivated Varicella-Zoster Virus (VZV) Vaccine in Adults With Hematologic Malignancies (HM) Receiving Treatment With Anti-Cluster of Differentiation (CD) 20 Monoclonal Antibodies (V212-013)

Herpes Zoster
Merck Sharp & Dohme LLC

Completed

A Study of Doravirine (MK-1439) in Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Participants (MK-1439-005)

HIV-1 Infection
Merck Sharp & Dohme LLC

Completed

A Study to Assess the Clinical Effects of Navarixin in Participants With Psoriasis (MK-7123-009)

Psoriasis
Merck Sharp & Dohme LLC

Completed

A Study to Determine the Optimal Dose of Tildrakizumab (SCH 900222/MK-3222) for the Treatment of Moderate-to-severe Chronic Plaque Psoriasis (P05495) (MK-3222-003)

Psoriasis
Merck Sharp & Dohme LLC

Completed

The Incidence of Extra-Articular Manifestations in Participants With Ankylosing Spondylitis Treated With Golimumab (MK-8259-012) (GO-EASY)

Ankylosing Spondylitis
Merck Sharp & Dohme LLC

Completed

A Study of the Efficacy and Safety of Vibegron (MK-4618) in Participants With Overactive Bladder (OAB) (MK-4618-008)

Urinary Bladder, Overactive
Merck Sharp & Dohme LLC

Completed

Efficacy and Safety of Org 25969 Administered After Zemuron® (MK-8616-042)

Neuromuscular Blockade
Merck Sharp & Dohme LLC

Completed

Sugammadex Hypersensitivity Study (Study P06042)

Hypersensitivity
Merck Sharp & Dohme LLC

Completed

Safety,Tolerability and Immunogenicity of Vaccination With VARIVAX in Healthy Indian Children (V210-056)

Varicella
Merck Sharp & Dohme LLC

Completed

A Study of MK-6213 Co-Administered With Atorvastatin in Participants With Hypercholesterolemia (MK-6213-006)

Hypercholesterolemia
Merck Sharp & Dohme LLC

Completed

Pharmacokinetics of MK-3682B in Participants With Moderate to Severe Renal Insufficiency (MK-3682B-030)

Hepatitis C
Merck Sharp & Dohme LLC

Completed

Efficacy and Safety of Navarixin (SCH 527123) in Participants With Allergen-Induced Asthma (P05363)

Asthma
Merck Sharp & Dohme LLC

Terminated

Study to Evaluate the Safety and Dose-Range of Navarixin (SCH 527123, MK-7123) in Participants With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (MK-7123-012)

Chronic Obstructive Pulmonary Disease
Merck Sharp & Dohme LLC

Completed

A Single-Dose Study of the Pharmacokinetics of Vibegron (MK-4618) in Adults With Hepatic Insufficiency (MK-4618-013)

Overactive Bladder
Merck Sharp & Dohme LLC

Completed

Immunogenicity and Tolerability of V503 Versus GARDASIL (V503-009)

Human Papillomavirus
Merck Sharp & Dohme LLC

Completed

Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of MK-8892 in Participants With Pulmonary Arterial Hypertension (PAH) (MK-8892-005)

Pulmonary Arterial Hypertension
Merck Sharp & Dohme LLC

Approved for marketing

Single Patient Treatment of Posaconazole in Invasive Fungal Infections (Study P05113)

Mycoses
Merck Sharp & Dohme LLC

Completed

V501 Safety and Efficacy Study in Japanese Women Aged 16 to 26 Years (V501-110)

Cervical Cancer | Cervical Intraepithelial Neoplasia | Adenocarcinoma in Situ
Merck Sharp & Dohme LLC

Completed

Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001)

Cervical Cancer | Vulvar Cancer | Vaginal Cancer | Human Papillomavirus Infection | Genital Warts
Merck Sharp & Dohme LLC

Completed

Immunogenicity and Safety of Concomitant Administration of RotaTeq™ (V260) and the Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus Vaccine (DTP-IPV) in Healthy Japanese Infants (V260-060)

Rotavirus Disease
Merck Sharp & Dohme LLC

Completed

A Study of the Immunogenicity, Tolerability, and Safety of a New Formulation of RotaTeq™ in Infants (V260-035)

Rotavirus Gastroenteritis
Merck Sharp & Dohme LLC

Completed

A Multiple-Dose Study to Evaluate MK-1075 in Hepatitis C Virus (HCV) Infected Participants (MK-1075-004)

Hepatitis C Virus Infection
Merck Sharp & Dohme LLC

Completed

Dyskinesia in Parkinson's Disease (Study P04501)

Brain Diseases | Central Nervous System Diseases | Parkinson Disease | Movement Disorders | Neurodegenerative Diseases
Merck Sharp & Dohme LLC

Terminated

Study of Preladenant for the Treatment of Antipsychotic Induced Movement Disorders in Participants With Schizophrenia (Study P04628)

Parkinsonian Disorders | Dyskinesia, Drug-Induced | Akathisia, Drug-Induced
Merck Sharp & Dohme LLC

Completed

A Dose Finding Study of Preladenant (SCH 420814) for the Treatment of Parkinson's Disease (PD) in Japanese Patients (P06402)

Parkinson's Disease
Merck Sharp & Dohme LLC

Terminated

[18F]MK-3328 as a Possible Novel Positron Emission Tomography (PET) Tracer for the Detection of Brain Amyloid Plaques (MK-3328-002)

Alzheimer's Disease
Merck Sharp & Dohme LLC

Terminated

A Placebo- and Active-Controlled Study of Preladenant in Early Parkinson's Disease (PD) (P05664) (PARADYSE)

Parkinson Disease
Merck Sharp & Dohme LLC

Completed

A Study of the Safety and Efficacy of MK-6096 for Migraine Prophylaxis in Participants With Episodic Migraine (MK-6096-020)

Migraine | Headache
Merck Sharp & Dohme LLC

Terminated

Safety and Efficacy of MK-6096 as Adjunctive Therapy in Participants With Major Depressive Disorder And Partial Response to Antidepressant Monotherapy (MK-6096-022)

Major Depressive Disorder, Recurrent
Merck Sharp & Dohme LLC

Completed

Trial to Determine the Maximum Tolerated Dose (MTD) Based on Safety and Tolerability, of Org 26576 in Participants With Major Depressive Disorder (174001/P05704/MK-8777-001)

Depression
Merck Sharp & Dohme LLC

Completed

Polysomnography Study of MK-6096 in Participants With Primary Insomnia (MK-6096-011)

Primary Insomnia
Merck Sharp & Dohme LLC

Completed

Pharmacokinetics of Suvorexant in Participants With Impaired Renal Function (MK-4305-023)(COMPLETED)

Insomnia
Merck Sharp & Dohme LLC

Completed

Phase IIB 2-Period Crossover Polysomnography Study in Participants With Primary Insomnia (MK-4305-006)

Primary Insomnia
Merck Sharp & Dohme LLC

Completed

Revaccination With PNEUMOVAX™ 23 in Older Japanese Adults (V110-902)

Pneumococcal Infection
Merck Sharp & Dohme LLC

Completed

Study to Evaluate Immunogenicity, Safety, and Tolerability of ZOSTAVAX™ Vaccine (Zoster Vaccine Live, V211) Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated) in Participants ≥50 Years of Age (V211-062)

Herpes Zoster
Merck Sharp & Dohme LLC

Completed

Safety, Pharmacokinetics, and Pharmacodynamics of MK-8876 in Participants With Hepatitis C Infection (MK-8876-003)

Hepatitis C
Merck Sharp & Dohme LLC

Terminated

Efficacy and Safety of Short Course Therapy With Peginterferon Alpha-2b (PEG-IFN Alfa-2b) and Ribavirin (RBV) for Chronic Hepatitis C (Genotype 4) Participants Achieving a Rapid Virological Response at Week 4 of Treatment (MK-8908B-059) (START 4)

Hepatitis C, Chronic

3

Subscribe